The French government has intervened to stop satellite operator Eutelsat from selling its ground antenna assets, framing the move as a defense of European strategic autonomy against rivals like SpaceX's Starlink.
Tesla is pivoting its core strategy, phasing out legacy Model S and X production to mass-manufacture Optimus humanoid robots and deepening its commitment to artificial intelligence with a major investment in Elon Musk's xAI. This strategic realignment signals a future where the company's identity may evolve from electric vehicle pioneer to a broader AI and robotics powerhouse.
Origin Bancorp (OBK) executives detailed strong profitability gains and a strategic hiring push, positioning the bank to capitalize on merger-driven market shifts and surpass $10 billion in assets.
A sharp sell-off across digital assets triggered over $1.7 billion in leveraged position liquidations, with Bitcoin and Ethereum leading the losses as market sentiment hits 'extreme fear' levels.
Colony Bankcorp (CBAN) reported improved operating performance in Q4 2025, with executives detailing on-track integration of TC Federal and momentum in fee-based businesses. The bank targets a 1.20% return on assets for 2026 and signals appetite for further acquisitions.
The iconic Berkeley-born coffee chain Peet's is closing dozens of locations across California, including in Southern California and the Bay Area, as part of a strategic realignment following its acquisition by Keurig Dr Pepper. The move, affecting hundreds of employees, has drawn sharp criticism from workers and union representatives.
A new analysis reveals the stark reality of homeownership in California, where residents in its largest cities are spending a historically high share of income on housing, pushing the dream of owning a home out of reach for many.
As a profitable outlier in a battered sector, Ethos Technologies' successful IPO marks a pivotal test for investor appetite in 2026's tech listings, even as its debut valuation reflects a more sober market reality.
The U.S. dollar extended its weekly decline as fresh geopolitical risks, including new tariff threats over Cuba and potential military action against Iran, dampened appetite for American assets, despite domestic political relief.
Wall Street analysts have issued a revised price target for Zillow Group, signaling a recalibration of expectations around the online real estate giant's business model and competitive standing in a shifting market.
Lumen Technologies pivots decisively toward the enterprise sector, achieving a pioneering AI management certification while divesting its remaining consumer fiber assets to AT&T, signaling a strategic consolidation around business and government services.
While speculative 'story stocks' capture headlines, Axis Real Estate Investment Trust (KLSE:AXREIT) presents a compelling case for investors seeking stability through consistent earnings growth and strong insider alignment.
Once a high-flying AI discovery platform, AbCellera Biologics is navigating a critical transition to a clinical-stage biotech. With a fortified balance sheet and key Phase 1 readouts on the horizon, some investors see a compelling, albeit risky, turnaround story taking shape.
Amid surging power demands from AI and electrification, NANO Nuclear Energy Inc. (NNE) is attracting bullish investor attention. Analysts point to its microreactor technology as a potential solution for decentralized, high-density energy needs, drawing comparisons to infrastructure giant NextEra Energy's growth trajectory.
Amid market volatility, Chevron Corporation (CVX) is drawing investor attention for its resilient cash generation and a 38-year record of dividend growth. Analysts highlight its integrated model and strategic assets as buffers against commodity price swings, positioning it as a cornerstone for income-focused portfolios.
Gilead Sciences, the biopharma giant known for its HIV treatments, is strategically pivoting to become a major player in cancer therapy. Through targeted licensing and a focus on precision oncology, the company aims to build a multi-billion dollar revenue stream by the end of the decade, reducing its reliance on mature franchises.
Facing the looming patent expiration of key drugs Revlimid and Eliquis, Bristol-Myers Squibb is making a strategic pivot, acquiring Orbital Therapeutics for $1.5 billion to pioneer in vivo RNA therapies. This high-stakes move aims to redefine the company's growth in oncology and autoimmune diseases.
AbbVie's $2.1 billion acquisition of Capstan Therapeutics signals a strategic pivot towards next-generation immunology treatments. The move aims to secure future revenue streams as the company navigates the post-Humira era, with analysts highlighting the transformative potential of its in vivo CAR-T platform.
The aerospace and engine leasing specialist defied a mid-year slump with a powerful earnings beat, propelling its stock to a stellar annual gain. Now, with the launch of its FTAI Power data center initiative, the company is aiming to capitalize on the AI-driven energy crunch.
A recent SEC filing reveals a major purchase of the Vanguard 0-3 Month Treasury Bill ETF, signaling a strategic move for liquidity and yield in a volatile market.
